RCW 69.41.193
Dispensing of biological product—Entry of product into electronic records system—Communication—Exceptions. (Expires August 1, 2025.)
(1) Within five business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee must make an entry of the specific product provided to the patient, including either the name of the product and the manufacturer or the federal food and drug administration's national drug code, provided that the name of the product and the name of the manufacturer are accessible to a practitioner in an electronic records system that can be electronically accessed by the patient's practitioner through:
(a) An interoperable electronic medical records system;
(b) An electronic prescribing technology;
(c) A pharmacy benefit management system; or
(d) A pharmacy record.
(2) Entry into an electronic records system, as described in subsection (1) of this section, is presumed to provide notice to the practitioner. Otherwise, the pharmacist must communicate to the practitioner the specific product provided to the patient, including the name of the product and manufacturer, using facsimile, telephone, electronic transmission, or other prevailing means.
(3) No entry or communication pursuant to this section is required if:
(a) There is no interchangeable biological product for the product prescribed;
(b) A refill prescription is not changed from the product dispensed on the prior filling of the prescription; or
(c) The pharmacist or the pharmacist's designee and the practitioner communicated before dispensing and the communication included confirmation of the specific product to be provided to the patient, including the name of the product and the manufacturer.
(4) This section expires August 1, 2025.
[ 2020 c 21 § 1; 2015 c 242 § 4.]
Structure Revised Code of Washington
Title 69 - Food, Drugs, Cosmetics, and Poisons
Chapter 69.41 - Legend Drugs—Prescription Drugs.
69.41.020 - Prohibited acts—Information not privileged communication.
69.41.032 - Prescription of legend drugs and dialysate by dialysis programs.
69.41.040 - Prescription requirements—Penalty.
69.41.042 - Record requirements.
69.41.050 - Labeling requirements—Penalty.
69.41.060 - Search and seizure.
69.41.062 - Search and seizure at rental premises—Notification of landlord.
69.41.065 - Violations—Juvenile driving privileges.
69.41.072 - Violations of chapter 69.50 RCW not to be charged under chapter 69.41 RCW—Exception.
69.41.075 - Rules—Availability of lists of drugs.
69.41.080 - Animal control—Rules for possession and use of legend drugs.
69.41.085 - Medication assistance—Community-based care setting.
69.41.095 - Opioid overdose reversal medication—Standing order permitted.
69.41.100 - Legislative recognition and declaration.
69.41.130 - Savings in price to be passed on to purchaser.
69.41.140 - Minimum manufacturing standards and practices.
69.41.150 - Liability of practitioner, pharmacist.
69.41.160 - Pharmacy signs as to substitution for prescribed drugs.
69.41.170 - Coercion of pharmacist prohibited—Penalty.
69.41.190 - Preferred drug substitution—Exceptions—Notice—Limited restrictions.
69.41.200 - Requirements for identification of legend drugs—Marking.
69.41.220 - Published lists of drug imprints—Requirements for.
69.41.230 - Drugs in violation are contraband.
69.41.240 - Rules—Labeling and marking.
69.41.260 - Manufacture or distribution for resale—Requirements.
69.41.320 - Practitioners—Restricted use—Medical records.
69.41.330 - Public warnings—School districts.